DDL 22 committee member Mark Hammond has organized a new group on LinkedIn called "DDL Conference" in order to "provide updates to the programme and this years conference as they become available and also give an opportunity to suggest topics/speakers and promote discussion and networking amongst our delegates." DDL22 will take place December 7-9, 2011 at the … [Read more...] about New LinkedIn group for DDL Conference
News
Phase 1 trial of inhaled atropine completed
A Phase 1 clinical trial of an inhaled dry powder formulation of atropine for the treatment of nerve agent poisoning has been completed successfully, according to MicroDose Therapeutx. MicroDose subsidiary MicroDose Defense Products is developing the product for the US Department of Defense. The study, conducted at the University of Pittsburgh Medical Center, … [Read more...] about Phase 1 trial of inhaled atropine completed
Copley Scientific to introduce new breath simulator
Copley Scientific will introduce its new breath simulator at the upcoming ISAM 2011 congress in Rotterdam, The Netherlands. New pharmacopoeial testing specifications for nebulizers take effect in August 2011, and the new breath simulator allows users to comply with the new requirements. The upcoming pharmacopoeial monographs, USP chapter 1601 and Ph. Eur 2.9.44, … [Read more...] about Copley Scientific to introduce new breath simulator
FDA accepts NDA for Nycomed nasal aerosol
The US FDA has accepted the filing of the new drug application for its ciclesonide nasal aerosol, according to Nycomed and Sunovion. The product is an HFA formulation of ciclesonide delivered by a metered dose device for the treatment of seasonal allergic rhinitis and perennial allergic rhinitis in patients 12 years old and older. Sunovion (formerly Sepracor) owns the … [Read more...] about FDA accepts NDA for Nycomed nasal aerosol
Asmacure announces new CEO
Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company "to pursue other business ventures." Asmacure is developing an inhaled nictonic receptor agonist, ASM-024, as a treatment for asthma. Driscoll worked most recently as CEO of Javelin Pharmaceuticals, which merged … [Read more...] about Asmacure announces new CEO
Two Phase 3 studies of Relovair completed
GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol. The companies said that the studies demonstrated statistically significant change in 0-4 hour weighted mean FEV1 and trough FEV1 for patients treated with Relovair compared with … [Read more...] about Two Phase 3 studies of Relovair completed
Aptar Classic modular pump chosen for Sprix nasal spray
Aptar Pharma is touting the use of its "Classic" modular spray pump in the recently launched Sprix ketorolac tromethamine nasal spray from Regency Therapeutics. Regency is a new division of Luitpold Pharmaceuticals, which acquired Sprix developer Roxro in December 2010. Aptar had worked with Roxro for 7 years on development of the product, and Eric Hohenschuh, … [Read more...] about Aptar Classic modular pump chosen for Sprix nasal spray
Generex licenses RapidMist technology
Generex Biotechnology has reached an agreement with Amarantus BioSciences regarding Generex's RapidMist buccal aerosol delivery system. The RapidMist device is a modified metered dose inhaler that delivers the aerosol to the lining of the mouth instead of to the lungs. Amarantus, which is paying Generex $10 million for use of the technology, will use it to deliver … [Read more...] about Generex licenses RapidMist technology
Rigel raises $130 million in stock offering
Rigel Pharmaceuticals has said that it is raising approximately $130.4 million as the result of a stock offering involving 16.3 million new shares. The company says that it expects the offer to close on or about June 1, 2011. Pfizer recently returned the rights to Rigel's inhaled syk inhibitor, R343. R343 is ready to move into Phase 2 trials, and the money raised … [Read more...] about Rigel raises $130 million in stock offering
MAP Pharmaceuticals submits NDA for Levadex
MAP Pharmaceuticals has submitted a new drug application (NDA) to the US FDA for its Levadex inhaled dihydroergotamine (DHE) for the treatment of migraines. The delivery device used for the product is the company's proprietary breath-activated MDI, the Tempo inhaler. MAP recently published data from its Phase 3 FREEDOM-301 trial, in which Levadex met all 4 primary … [Read more...] about MAP Pharmaceuticals submits NDA for Levadex